Vutrisiran, a new drug made by Alnylam Pharmaceuticals to treat ATTR amyloidosis with cardiomyopathy, reduced the risk of death by 36% in patients, the drugmaker announced June 24.
Overall, in phase 3 trials, vutrisiran caused almost no adverse events in patients.
"[V]utrisiran has the potential to address the needs of patients with ATTR amyloidosis with cardiomyopathy, a steadily progressive, debilitating, and ultimately fatal disease," Pushkal Garg, MD, chief medical officer of Alnylam, said in a news release. "The results showed that vutrisiran improved cardiovascular outcomes, including survival, function and quality of life in all patient groups with ATTR cardiomyopathy."
The drug's benefits were consistent across various patient groups and improved walking ability, symptoms of heart failure and quality of life, according to the release, including in patients also taking tafamidis, a separate drug, taken orally, that's used to treat cardiomyopathy and peripheral neuropathy.
Alnylam will next seek FDA approval for the drug.
"We are moving with urgency to file these compelling data with regulators to bring this medicine to patients around the world," Dr. Garg said.